LRB-2842/1
CMH:cdc
2023 - 2024 LEGISLATURE
2023 ASSEMBLY JOINT RESOLUTIO N 49
May 25, 2023 - Introduced by Representatives MURPHY, CABRERA, DRAKE, OHNSTAD,
ROZAR, SHANKLAND, SINICKI and C LANCY, cosponsored by Senators
CABRAL-GUEVARA, COWLES, ROYS and SPREITZER. Referred to Committee on
Rules.
***AUTHORS SUBJECT TO CHANGE***
Relating to: designating Hypertrophic Cardiomyopathy Awareness Day and efforts
to educate people about hypertrophic cardiomyopathy.
Whereas, Hypertrophic Cardiomyopathy (HCM) is a chronic cardiovascular
disease involving thickening of the heart muscle and can potentially lead to
debilitating symptoms and serious complications including heart failure, atrial
fibrillation, stroke, and in rare cases sudden cardiac death; and
Whereas, HCM is the most common inheritable heart disease and can affect
anyone regardless of age, gender, or ethnicity with a reported prevalence ranging
from 1 in 200 to 1 in 500 in the general population; and
Whereas, an estimated 700,000 to 1,650,000 people in the United States have
HCM, yet 85 percent of them may remain undiagnosed; and
Whereas, HCM shares symptoms with other common cardiovascular and
pulmonary diseases, such as shortness of breath, chest pain, fatigue, palpitations,
and fainting, making it difficult to distinguish HCM from these other diseases; and
1
2
3
4
5
6
7
8
9
10
11
12
13
14 - 2 -
LRB-2842/1
CMH:cdc
2023 - 2024 Legislature
Whereas, all-cause mortality risk is three to four times higher in patients with
HCM than that of the general population; and
Whereas, knowing one's medical history and any signs and symptoms of HCM
is an important first step in receiving an accurate diagnosis of HCM; and
Whereas, a healthcare provider must conduct a thorough screening with
cardiac health questions to help identify a risk of cardiac disorders both genetic and
congenital; and
Whereas, a health-care provider may conduct several tests, including an
echocardiogram, a cardiac MRI, or genetic testing to confirm a family history of
HCM, and must examine the heart to diagnose HCM; and
Whereas, following a diagnosis of HCM, it is important for patients to work with
their healthcare provider to learn more about their disease and understand different
management options, including prescription medicines and surgical treatment
options that may help; and
Whereas, the fourth Wednesday in February is an appropriate day to observe
Hypertrophic Cardiomyopathy Awareness Day; now, therefore, be it
Resolved by the assembly, the senate concurring, That the Wisconsin
Legislature designates the fourth Wednesday in February of each year as
“Hypertrophic Cardiomyopathy Awareness Day” in Wisconsin in order to raise public
awareness about hypertrophic cardiomyopathy; and, be it further
Resolved, That the Wisconsin Legislature acknowledges the critical
importance of hypertrophic cardiomyopathy awareness to improve cardiovascular
health in Wisconsin; and, be it further
Resolved, That the Wisconsin Legislature supports raising awareness of the
consequences of undiagnosed and untreated hypertrophic cardiomyopathy and the
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25 - 3 -
LRB-2842/1
CMH:cdc
2023 - 2024 Legislature
need to seek appropriate care for hypertrophic cardiomyopathy as a serious public
health issue; and, be it further
Resolved, That the Wisconsin Legislature respectfully requests the Governor
to issue annually a proclamation recognizing the fourth Wednesday in February in
as “Hypertrophic Cardiomyopathy Awareness Day” in Wisconsin and calls upon the
people in this state to observe the day with appropriate programs and activities.
(END)
1
2
3
4
5
6
7